TickerGuard
Buy Day today: Neutral (55) Mixed market breadth · major macro event coming up
IMVT

Immunovant Inc

Healthcare · Biotechnology

29.00$ +2.2% vs. previous close Closing price · As of: Nov 3, 2026

Ownership

Ownership Structure

Who owns Immunovant Inc (IMVT)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 44.4% of the shares are freely tradable; institutional investors hold 54.7%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 54.7%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 56.7%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 44.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 18.7%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 207Mio.

Largest Shareholders

Institutions

Institutions IMVT
Name Stake (%) Shares Change (%) Date
FMR Inc 7.84 16,186,469 -4.5 06/30/2026
Deep Track Capital, LP 4.52 9,341,151 -19.0 06/30/2026
BlackRock Inc 3.48 7,180,897 +9.2 06/30/2026
Farallon Capital Management, L.L.C. 2.81 5,805,000 +275.5 06/30/2026
Baker Bros Advisors LP 2.63 5,435,220 -0.4 06/30/2026
State Street Corp 2.24 4,617,005 +1.7 06/30/2026
Morgan Stanley - Brokerage Accounts 2.20 4,534,833 +17.0 06/30/2026
TCG Crossover Management, LLC 2.16 4,457,988 +0.0 06/30/2026
Vanguard Portfolio Management, LLC 1.89 3,910,509 +5.5 06/30/2026

Funds

Funds IMVT
Name Stake (%) Shares Change (%) Date
Fidelity Growth Company Fund 2.47 5,092,337 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Insider holdings

Insider holdings IMVT
Person Role Shares Value As of Type
Venker Eric Chief Executive Officer 257,075 7,455,175 $ Oct 2, 2026 direct
Girao Tiago Chief Financial Officer 234,192 6,791,568 $ Oct 28, 2026 direct
Gloria Melanie Chief Operating Officer 217,060 6,294,740 $ Oct 7, 2026 direct
Stout Jay S Chief Technology Officer 198,937 5,769,173 $ Oct 21, 2026 direct
Van Tuyl Christopher Chief Legal Officer 175,218 5,081,322 $ Oct 7, 2026 direct
Pande Atul Director 116,731 3,385,199 $ Aug 28, 2026 direct

Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.

Insiders

Insider Transactions

Insider Transactions
Date Person Role Type Shares Price Value
Oct 28, 2026 Girao Tiago Chief Financial Officer Sell 6,606 28.50 188,271
Oct 21, 2026 Stout Jay S Chief Technology Officer Sell 2,595 28.94 75,099
Oct 7, 2026 Van Tuyl Christopher Chief Legal Officer Sell 1,327 32.06 42,544
Oct 7, 2026 Gloria Melanie Chief Operating Officer Sell 2,241 32.06 71,846
Oct 7, 2026 Stout Jay S Chief Technology Officer Sell 1,596 32.06 51,168
Oct 7, 2026 Stout Jay S Chief Technology Officer Sell 2,213 32.06 70,949
Oct 2, 2026 Venker Eric Chief Executive Officer Sell 3,506 34.11 119,590
Oct 1, 2026 Venker Eric Chief Executive Officer Other 85,886 33.65 2,890,064
Oct 1, 2026 Venker Eric Chief Executive Officer Other 92,187 14.46 1,333,024
Sep 23, 2026 Van Tuyl Christopher Chief Legal Officer Sell 2,846 36.36 103,481
Aug 28, 2026 Pande Atul Director Sell 1,500 43.27 64,905
Aug 28, 2026 Pande Atul Director Other 1,500 8.43 12,645
Aug 20, 2026 Gloria Melanie Chief Operating Officer Sell 3,056 44.16 134,953
Apr 23, 2026 Jay S Stout CTO Sell 2,754 29.62 81,573
Apr 23, 2026 Tiago Girao CFO Sell 25,760 29.62 763,011

Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →

Data as of: November 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?